Full Press Release Details
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcell, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B.
ALT
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcell, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
Key Takeaway: Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcell, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight